Drug Class: Immunotherapy

Immune Cell Stimulators: IDO

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02178722 II Epacadostat, Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)

Epacadostat+pembrolizumab combination shows encouraging anti-tumor activity with acceptable safety

ORR: 8%
DCR: 35%

abs Jun 2017

< Return to Drug Classes

< Return to Clinical Trial Results Homepage